WINNIPEG, Manitoba – (October 21, 2011) Medicure Inc. ("Medicure" or the "Company") (NEX:MPH.H / TSXV:MPH, OTC:MCUJ.PK) is pleased to announce that the TSX Venture Exchange has granted approval for Medicure to graduate from the NEX, to the TSX Venture Exchange as a Tier 2 issuer. Medicure’s shares will commence trading on the TSX Venture Exchange on Monday, October 24, 2011. The Company’s trading symbol will also change from MPH.H to MPH.
"Graduation onto the TSX Venture Exchange represents a significant milestone for the Company, and is one that could not have been accomplished without the successful debt restructuring and related transactions announced on July 18, 2011," commented Dawson Reimer, President and COO of Medicure Inc. "In addition to allowing us to meet the listing requirements of the TSX Venture Exchange, our recent developments have provided a renewed basis for us to advance our US focused, specialty pharmaceutical business."
About Medicure Inc.
Medicure is a specialty pharmaceutical company focused on the development and commercialization of novel small molecule therapeutics. The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT® (tirofiban HCl) for acute coronary syndromes in the United States, where it is sold through the Company’s US subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com.